• In early February 2026, Genpact reported fourth-quarter and full-year 2025 results showing higher sales and earnings versus 2024, raised its quarterly dividend to US$0.1875 per share, and completed a long-running share repurchase program totaling about US$2.39 billion since 2015.
• The company also issued 2026 guidance calling for at least 7% full-year revenue growth and higher earnings, underpinned by strong momentum in its fast-growing Advanced Technology Solutions and AI-focused offerings.
• With the shares posting a 8.41% seven-day swing and Genpact emphasizing Advanced Technology Solutions growth, we'll assess how this shapes its investment narrative.

AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Genpact's Investment Narrative?

For Genpact to make sense in a portfolio, you have to be comfortable with a services business that is slowly tilting its center of gravity toward data, AI and Advanced Technology Solutions, while still relying on a large, slower-growing core. The latest results and 2026 outlook reinforce that story: revenue and earnings climbed versus 2024, guidance points to mid‑single‑digit growth in the near term, and AI‑driven offerings are taking a bigger share of the mix. The 10% dividend increase and completion of a roughly US$2.39 billion buyback underline management’s confidence and help cushion what has been a weak one‑year total return. Near term, the key catalysts now sit squarely in sustaining high‑teens growth in Advanced Technology Solutions and converting strong AI bookings into revenue, while the main risks are softer legacy BPO demand, client spending pressure and the possibility that recent share price volatility is the market questioning how durable this AI‑led growth will be.

However, investors should also weigh how much slower legacy operations might drag on that AI growth story. Despite retreating, Genpact's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Three Simply Wall St Community valuations for Genpact range from about US$35 to over US$127 per share, highlighting very different expectations. Against that backdrop, the recent AI‑focused growth and dividend lift sit beside ongoing concerns about legacy BPO demand and client budgets, giving you several angles on how the business could perform from here.

Explore 3 other fair value estimates on Genpact - why the stock might be worth 13% less than the current price!

Build Your Own Genpact Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Genpact research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Genpact research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Genpact's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 52 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 28 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.